We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
Read MoreHide Full Article
Key Takeaways
JNJ agreed to acquire Firefly Bio for $1 billion in cash, expanding its oncology pipeline.
Firefly Bio's Firelink DAC platform is designed for cancers driven by KRAS mutations.
JNJ expects the deal to strengthen efforts in hard-to-treat solid tumors with limited options.
Johnson & Johnson (JNJ - Free Report) announced that it has entered into a definitive agreement to acquire California-based biotech, Firefly Bio, for $1 billion in cash.
The impending acquisition will add Firefly Bio’s proprietary Firelink degrader antibody conjugate (DAC) platform to JNJ’s pipeline.
Firefly Bio's Firelink DAC platform, which has been designed for cancers driven by KRAS mutations, is likely to strengthen J&J’s oncology pipeline. The deal is likely to support J&J's efforts to develop targeted treatments for some of the most common and difficult-to-treat solid tumors, where treatment options remain limited.
The transaction is expected to be closed later in 2026, subject to customary closing conditions.
The DAC platform is a new technology designed to overcome some of the limitations of existing cancer treatments by delivering a highly targeted protein degrader directly to tumor cells while minimizing damage to healthy cells.
JNJ Price Performance
Year to date, shares of J&J have risen 13.4% compared with the industry’s rise of 5.8%.
Image Source: Zacks Investment Research
JNJ Seeks Expansion With M&A Push
J&J has been on an acquisition spree in recent times. In 2025, the company invested more than $32 billion in R&D and M&A, including the acquisition of Intra-Cellular Therapies, which added the antidepressant drug Caplyta to JNJ’s neuroscience portfolio.
Caplyta is approved for the treatment of schizophrenia, depression in both bipolar 1 and 2, and major depressive disorder.
J&J is also building its oncology pipeline through M&A deals. Last year, it acquired Halda Therapeutics, which added a promising clinical-stage treatment for prostate cancer with potential across multiple tumor types.
The acquisition added Halda’s proprietary RIPTAC platform, a technology being used to develop oral, targeted therapies for multiple types of solid tumors.
J&J has also pursued various acquisitions to strengthen its presence in cardiovascular diseases and rare autoantibody-driven disorders.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share (EPS) have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.66 to $4.27. INDV shares have risen 4.2% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 85.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Immunocore’s 2026 have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 19.9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
Key Takeaways
Johnson & Johnson (JNJ - Free Report) announced that it has entered into a definitive agreement to acquire California-based biotech, Firefly Bio, for $1 billion in cash.
The impending acquisition will add Firefly Bio’s proprietary Firelink degrader antibody conjugate (DAC) platform to JNJ’s pipeline.
Firefly Bio's Firelink DAC platform, which has been designed for cancers driven by KRAS mutations, is likely to strengthen J&J’s oncology pipeline. The deal is likely to support J&J's efforts to develop targeted treatments for some of the most common and difficult-to-treat solid tumors, where treatment options remain limited.
The transaction is expected to be closed later in 2026, subject to customary closing conditions.
The DAC platform is a new technology designed to overcome some of the limitations of existing cancer treatments by delivering a highly targeted protein degrader directly to tumor cells while minimizing damage to healthy cells.
JNJ Price Performance
Year to date, shares of J&J have risen 13.4% compared with the industry’s rise of 5.8%.
Image Source: Zacks Investment Research
JNJ Seeks Expansion With M&A Push
J&J has been on an acquisition spree in recent times. In 2025, the company invested more than $32 billion in R&D and M&A, including the acquisition of Intra-Cellular Therapies, which added the antidepressant drug Caplyta to JNJ’s neuroscience portfolio.
Caplyta is approved for the treatment of schizophrenia, depression in both bipolar 1 and 2, and major depressive disorder.
J&J is also building its oncology pipeline through M&A deals. Last year, it acquired Halda Therapeutics, which added a promising clinical-stage treatment for prostate cancer with potential across multiple tumor types.
The acquisition added Halda’s proprietary RIPTAC platform, a technology being used to develop oral, targeted therapies for multiple types of solid tumors.
J&J has also pursued various acquisitions to strengthen its presence in cardiovascular diseases and rare autoantibody-driven disorders.
JNJ's Zacks Rank & Stocks to Consider
J&J currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share (EPS) have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.66 to $4.27. INDV shares have risen 4.2% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 85.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Immunocore’s 2026 have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 19.9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.